Clinical Trial Update: Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating adjuvant durvalumab plus regorafenib versus no treatment in stage IV colorectal cancer patients with no evidence of disease after prior…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Regorafenib (regorafenib)

Snippet

Sponsor: Ospedale Policlinico San Martino | Conditions: Colorectal Cancer Stage IV, No Evidence of Disease State | Phase 2 | Status: UNKNOWN